UNSPSC 51162712: Fudosteine

This classification denotes a mucolytic agent with the molecular formula C6H13NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) UR9VPI71PT, chemically known as l-cysteine, s-(3-hydroxypropyl)- but more generally known as fudosteine, which bears US NIH Compound Identifier 134669. European Medicines Agency schedules Fudosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07825MIG.

UNSPSC 51162712 Fudosteine, a Commodity code, covers pharmaceutical products and related supplies state and local governments procure for correctional health systems, public health agencies, and emergency response programs. Recent solicitations show state and local bodies buying intravenous nutrition solutions, parenteral products, naloxone, and drug deactivation systems for incarcerated populations and community health initiatives. The Washington State Department of Corrections and Seminole County, Florida have posted opportunities under this code, indicating activity across state correctional systems and county public health departments. Scope includes compounded parenteral nutrition bags (TPN and PPN), intravenous solutions, controlled substances, and related pharmaceutical delivery services with documented clinical preparation and patient monitoring capabilities. Contractors typically must demonstrate experience preparing and delivering time-sensitive parenteral products, maintaining specialized insurance including professional liability and cyber liability coverage, and complying with state business licensing and background clearance requirements.

The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, with a response deadline of October 7, 2026, soliciting parenteral products and services across eight correctional facilities in three regions (West, Central, and East), with an anticipated contract term running through June 30, 2030 and fixed pricing required for the initial two-year period. The solicitation emphasizes SBE, MBE, WBE, and VBE participation through Washington State set-asides and an aspirational 5% Small and Diverse Business Goal, with a Subcontractor Inclusion Plan required of primes. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Recent activity concentrates in Washington state and Florida, with state correctional systems and county health departments driving demand for both compounded pharmaceutical solutions and harm-reduction supplies. Delivery speed and quality assurance are critical — the Washington solicitation imposes strict timing requirements, with parenteral nutrition bags due within 24 hours and other products within 8 hours, and DOC refusing to pay for late deliveries.